Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): A trial of the Eastern Cooperative Oncology Group

Scott Heitaka Okuno, Louise M. Ryan, John H. Edmonson, Dennis A. Priebat, Ronald H. Blum

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

BACKGROUND. The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. METHODS. Twenty-five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Cooperative Oncology Group Phase II study. Patients ranged in age from 27 to 79 years, with a median age of 59 years. The most common histology was leiomyosarcoma (54%). The grades of the tumors were high in 40%, moderate in 24% and low in 12%. Gemcitabine was given at a dose of 1250 mg/m2 as a 30-minute infusion weekly for 3 weeks followed by 1 week of rest. RESULTS. One of the 25 patients (4%) (90% confidence interval [90% CI], 0-18%) achieved a partial response lasting 8 months. The estimated overall median survival was 15 months. The 1-year estimated survival rate was 63% (90% CI, 47-84%). The estimated median progression-free survival (PFS) was 13 months with a 1-year PFS rate of 56% (90% CI, 41-76%). Grade 3-4 toxicities (by CTC criteria) were observed in all 25 patients. No lethal toxicity (Grade 5) related to treatment was found. CONCLUSIONS. The results of the current study demonstrated that gemcitabine given at this schedule and dose in this population of patients with advanced sarcoma had limited activity.

Original languageEnglish (US)
Pages (from-to)1969-1973
Number of pages5
JournalCancer
Volume97
Issue number8
DOIs
StatePublished - Apr 15 2003

Fingerprint

gemcitabine
Sarcoma
Confidence Intervals
Disease-Free Survival
Survival Rate
Leiomyosarcoma
Histology
Appointments and Schedules

Keywords

  • Antitumor activity
  • Chemotherapy
  • Gemcitabine
  • Sarcoma
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group. / Okuno, Scott Heitaka; Ryan, Louise M.; Edmonson, John H.; Priebat, Dennis A.; Blum, Ronald H.

In: Cancer, Vol. 97, No. 8, 15.04.2003, p. 1969-1973.

Research output: Contribution to journalArticle

Okuno, Scott Heitaka ; Ryan, Louise M. ; Edmonson, John H. ; Priebat, Dennis A. ; Blum, Ronald H. / Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group. In: Cancer. 2003 ; Vol. 97, No. 8. pp. 1969-1973.
@article{e08d04b2c2ef4ecb86ed841a0b5aa88a,
title = "Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): A trial of the Eastern Cooperative Oncology Group",
abstract = "BACKGROUND. The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. METHODS. Twenty-five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Cooperative Oncology Group Phase II study. Patients ranged in age from 27 to 79 years, with a median age of 59 years. The most common histology was leiomyosarcoma (54{\%}). The grades of the tumors were high in 40{\%}, moderate in 24{\%} and low in 12{\%}. Gemcitabine was given at a dose of 1250 mg/m2 as a 30-minute infusion weekly for 3 weeks followed by 1 week of rest. RESULTS. One of the 25 patients (4{\%}) (90{\%} confidence interval [90{\%} CI], 0-18{\%}) achieved a partial response lasting 8 months. The estimated overall median survival was 15 months. The 1-year estimated survival rate was 63{\%} (90{\%} CI, 47-84{\%}). The estimated median progression-free survival (PFS) was 13 months with a 1-year PFS rate of 56{\%} (90{\%} CI, 41-76{\%}). Grade 3-4 toxicities (by CTC criteria) were observed in all 25 patients. No lethal toxicity (Grade 5) related to treatment was found. CONCLUSIONS. The results of the current study demonstrated that gemcitabine given at this schedule and dose in this population of patients with advanced sarcoma had limited activity.",
keywords = "Antitumor activity, Chemotherapy, Gemcitabine, Sarcoma, Toxicity",
author = "Okuno, {Scott Heitaka} and Ryan, {Louise M.} and Edmonson, {John H.} and Priebat, {Dennis A.} and Blum, {Ronald H.}",
year = "2003",
month = "4",
day = "15",
doi = "10.1002/cncr.11290",
language = "English (US)",
volume = "97",
pages = "1969--1973",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Phase II trial of gemcitabine in patients with advanced sarcomas (E1797)

T2 - A trial of the Eastern Cooperative Oncology Group

AU - Okuno, Scott Heitaka

AU - Ryan, Louise M.

AU - Edmonson, John H.

AU - Priebat, Dennis A.

AU - Blum, Ronald H.

PY - 2003/4/15

Y1 - 2003/4/15

N2 - BACKGROUND. The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. METHODS. Twenty-five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Cooperative Oncology Group Phase II study. Patients ranged in age from 27 to 79 years, with a median age of 59 years. The most common histology was leiomyosarcoma (54%). The grades of the tumors were high in 40%, moderate in 24% and low in 12%. Gemcitabine was given at a dose of 1250 mg/m2 as a 30-minute infusion weekly for 3 weeks followed by 1 week of rest. RESULTS. One of the 25 patients (4%) (90% confidence interval [90% CI], 0-18%) achieved a partial response lasting 8 months. The estimated overall median survival was 15 months. The 1-year estimated survival rate was 63% (90% CI, 47-84%). The estimated median progression-free survival (PFS) was 13 months with a 1-year PFS rate of 56% (90% CI, 41-76%). Grade 3-4 toxicities (by CTC criteria) were observed in all 25 patients. No lethal toxicity (Grade 5) related to treatment was found. CONCLUSIONS. The results of the current study demonstrated that gemcitabine given at this schedule and dose in this population of patients with advanced sarcoma had limited activity.

AB - BACKGROUND. The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. METHODS. Twenty-five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Cooperative Oncology Group Phase II study. Patients ranged in age from 27 to 79 years, with a median age of 59 years. The most common histology was leiomyosarcoma (54%). The grades of the tumors were high in 40%, moderate in 24% and low in 12%. Gemcitabine was given at a dose of 1250 mg/m2 as a 30-minute infusion weekly for 3 weeks followed by 1 week of rest. RESULTS. One of the 25 patients (4%) (90% confidence interval [90% CI], 0-18%) achieved a partial response lasting 8 months. The estimated overall median survival was 15 months. The 1-year estimated survival rate was 63% (90% CI, 47-84%). The estimated median progression-free survival (PFS) was 13 months with a 1-year PFS rate of 56% (90% CI, 41-76%). Grade 3-4 toxicities (by CTC criteria) were observed in all 25 patients. No lethal toxicity (Grade 5) related to treatment was found. CONCLUSIONS. The results of the current study demonstrated that gemcitabine given at this schedule and dose in this population of patients with advanced sarcoma had limited activity.

KW - Antitumor activity

KW - Chemotherapy

KW - Gemcitabine

KW - Sarcoma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0344839034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344839034&partnerID=8YFLogxK

U2 - 10.1002/cncr.11290

DO - 10.1002/cncr.11290

M3 - Article

C2 - 12673725

AN - SCOPUS:0344839034

VL - 97

SP - 1969

EP - 1973

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -